Enhabit, Inc. (NYSE:EHAB) Given Consensus Recommendation of “Hold” by Brokerages

Enhabit, Inc. (NYSE:EHAB) has been given an average rating of “Hold” by the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $8.75.

Several research firms have recently issued reports on EHAB. Jefferies Financial Group upgraded Enhabit from a “hold” rating to a “buy” rating and boosted their target price for the stock from $8.25 to $9.50 in a research report on Monday, December 9th. Leerink Partners restated a “market perform” rating and set a $8.00 price objective (down previously from $8.50) on shares of Enhabit in a report on Tuesday, November 19th.

Insider Transactions at Enhabit

In related news, Director Stuart M. Mcguigan acquired 15,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was bought at an average price of $8.81 per share, with a total value of $132,150.00. Following the completion of the transaction, the director now directly owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. The trade was a 47.15 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bolton acquired 4,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the transaction, the director now directly owns 98,144 shares in the company, valued at $852,871.36. This represents a 4.25 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC lifted its stake in Enhabit by 138.4% in the 3rd quarter. FMR LLC now owns 3,388 shares of the company’s stock valued at $27,000 after acquiring an additional 1,967 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Enhabit in the fourth quarter valued at approximately $45,000. Gladius Capital Management LP lifted its position in shares of Enhabit by 78.2% in the third quarter. Gladius Capital Management LP now owns 6,259 shares of the company’s stock worth $49,000 after purchasing an additional 2,747 shares in the last quarter. Group One Trading LLC boosted its holdings in Enhabit by 248.3% during the fourth quarter. Group One Trading LLC now owns 7,746 shares of the company’s stock worth $60,000 after purchasing an additional 5,522 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new position in Enhabit in the fourth quarter valued at $79,000.

Enhabit Price Performance

Shares of Enhabit stock opened at $8.26 on Thursday. The business has a fifty day simple moving average of $8.10 and a 200 day simple moving average of $7.90. The stock has a market cap of $415.35 million, a PE ratio of -3.56 and a beta of 1.83. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85. Enhabit has a 12 month low of $6.85 and a 12 month high of $11.74.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.